Gregory J Kato

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Priapism in sickle-cell disease: a hematologist's perspective
    Gregory J Kato
    National Heart, Lung and Blood Institute, National Institutes of Health Sickle Cell Vascular Disease Section, Cardiovascular and Pulmonary Branch, Bethesda, MD 20892 1476, USA
    J Sex Med 9:70-8. 2012
  2. pmc Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy
    Gregory J Kato
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Dr, MSC 1476, Bldg 10 CRC, Room 5 5140, Bethesda, MD 20892 1476, USA
    JAMA 300:2638-46. 2008
  3. pmc Pleiotropic effects of intravascular haemolysis on vascular homeostasis
    Gregory J Kato
    Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute and the Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Br J Haematol 148:690-701. 2010
  4. pmc Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions
    Gregory J Kato
    Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1476, USA
    Am J Hematol 84:618-25. 2009
  5. pmc Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death
    Gregory J Kato
    Critical Care Medicine Department, Clinical Center, NHLBI, NIH, Bethesda, MD 20892 1476, USA
    Br J Haematol 145:506-13. 2009
  6. pmc Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes
    Gregory J Kato
    Vascular Medicine Branch, National Heart, Lung and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Drive, Building 10CRC 5 5140, Bethesda, MD 20892 1476, USA
    Blood Rev 21:37-47. 2007
  7. pmc Cerebrovascular disease associated with sickle cell pulmonary hypertension
    Gregory J Kato
    Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1476, USA
    Am J Hematol 81:503-10. 2006
  8. pmc Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality
    Gregory J Kato
    Vascular Therapeutics Section, Cardiovascular Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA
    Br J Haematol 130:943-53. 2005
  9. pmc Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease
    Gregory J Kato
    Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Dr, MSC 1476, Bldg 10CRC, Rm 5 5140, Bethesda, MD 20892, USA
    Blood 107:2279-85. 2006
  10. pmc Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease
    Roberto F Machado
    Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Br J Haematol 136:319-25. 2007

Detail Information

Publications54

  1. pmc Priapism in sickle-cell disease: a hematologist's perspective
    Gregory J Kato
    National Heart, Lung and Blood Institute, National Institutes of Health Sickle Cell Vascular Disease Section, Cardiovascular and Pulmonary Branch, Bethesda, MD 20892 1476, USA
    J Sex Med 9:70-8. 2012
    ..It also occurs in a variety of other hematological illnesses, nearly all forms of congenital hemolytic anemia, including other hemoglobinopathies and red blood cell membranopathies and enzymopathies...
  2. pmc Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy
    Gregory J Kato
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Dr, MSC 1476, Bldg 10 CRC, Room 5 5140, Bethesda, MD 20892 1476, USA
    JAMA 300:2638-46. 2008
    ..This article reviews the pathophysiology of sickle vasculopathy and the results of preliminary clinical trials of novel small-molecule therapeutics directed at abnormal vascular biology in patients with sickle cell disease...
  3. pmc Pleiotropic effects of intravascular haemolysis on vascular homeostasis
    Gregory J Kato
    Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute and the Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Br J Haematol 148:690-701. 2010
    ..This article reviews the haemolytic disorders that have been reported to manifest vascular complications, and explores the speculative possibility that haemolysis mediates some of the vascular complications of inflammation and diabetes...
  4. pmc Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions
    Gregory J Kato
    Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892 1476, USA
    Am J Hematol 84:618-25. 2009
    ....
  5. pmc Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death
    Gregory J Kato
    Critical Care Medicine Department, Clinical Center, NHLBI, NIH, Bethesda, MD 20892 1476, USA
    Br J Haematol 145:506-13. 2009
    ..These defects and others converge on the nitric oxide pathway in homozygous SCD with vasculopathy...
  6. pmc Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes
    Gregory J Kato
    Vascular Medicine Branch, National Heart, Lung and Blood Institute, Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Drive, Building 10CRC 5 5140, Bethesda, MD 20892 1476, USA
    Blood Rev 21:37-47. 2007
    ..Some of these drugs are now being studied in clinical trials...
  7. pmc Cerebrovascular disease associated with sickle cell pulmonary hypertension
    Gregory J Kato
    Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1476, USA
    Am J Hematol 81:503-10. 2006
    ..Clinicians should suspect occult cerebrovascular disease in sickle cell patients with pulmonary hypertension...
  8. pmc Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality
    Gregory J Kato
    Vascular Therapeutics Section, Cardiovascular Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892, USA
    Br J Haematol 130:943-53. 2005
    ..Our data are consistent with steady state levels of soluble adhesion molecules as markers of pulmonary hypertension and risk of death...
  9. pmc Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease
    Gregory J Kato
    Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Dr, MSC 1476, Bldg 10CRC, Rm 5 5140, Bethesda, MD 20892, USA
    Blood 107:2279-85. 2006
    ..We propose that LDH elevation identifies patients with a syndrome of hemolysis-associated NO resistance, endothelial dysfunction, and end-organ vasculopathy...
  10. pmc Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease
    Roberto F Machado
    Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Br J Haematol 136:319-25. 2007
    ..001) in all subjects. These data suggest that acute elevations in pulmonary pressures during VOC or exercise may contribute to morbidity and mortality in patients with sickle cell disease...
  11. pmc Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin
    Jose Villagra
    Vascular Medicine Branch of National Heart, Lung, and Blood Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Blood 110:2166-72. 2007
    ..This supports a role for NO-based therapeutics for SCD vasculopathy. This trial was registered at www.clinicaltrials.gov as no. NCT00352430...
  12. pmc Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease
    Ashaunta Tumblin
    Pulmonary Brance, National Heart, Lung and Blood Institute, Bethesda, MD, USA
    Haematologica 95:1467-72. 2010
    ..Acute painful episodes are the clinical hallmark of sickle cell disease and have been linked to morbidity and mortality in the sickle cell population...
  13. pmc Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease
    Caterina P Minniti
    Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 147:737-43. 2009
    ..Therapy was stopped in two patients who were switched then to the other ETR blocker agent. These data suggest preliminary evidence for the benefit of bosentan and ambrisentan in pulmonary hypertension in SCD...
  14. pmc Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain
    James G Taylor
    Pulmonary and Vascular Medicine Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 3:e2095. 2008
    ..We have previously reported that intense hemolysis is associated with increased risk of vascular complications in a small cohort of adults with sickle cell disease. These observations have not been validated in other populations...
  15. pmc Increased pulmonary pressures and myocardial wall stress in children with severe malaria
    Jacqueline J Janka
    Clinical Center Critical Care Medicine Department and Pulmonary and Vascular Medicine and Translational Medicine Branches, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 202:791-800. 2010
    ..To test whether this pathophysiology occurs in malaria, we examined in Mali 53 children who were admitted to the hospital with severe malaria (excluding cerebral malaria) and 31 age-matched controls...
  16. pmc Liver stiffness increases acutely during sickle cell vaso-occlusive crisis
    Christopher Koh
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    Am J Hematol 88:E250-4. 2013
    ..Increase in TE may reflect both hepatic passive congestion and hepatic involvement during VOC. TE may serve as a physiological biomarker for hepatic features of VOC...
  17. ncbi request reprint N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease
    Roberto F Machado
    Vascular Medicine Branch, Clinical Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1454, USA
    JAMA 296:310-8. 2006
    ..Levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) provide such information in patients with idiopathic pulmonary arterial hypertension...
  18. pmc Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension
    Suzana Zorca
    Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 149:436-45. 2010
    ..05). These results characterize elevated plasma triglyceride levels as a potential risk factor for PH in SCD...
  19. pmc Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease
    James G Taylor
    Vascular Medicine Branch, NHLBI, NIH, Bethesda, Maryland 20892 1476, USA
    Am J Hematol 83:6-14. 2008
    ..Despite this protective association, patients with SC who did develop pulmonary hypertension remained at significant risk for death during 49 months of follow-up (Hazard Ratio=8.20, P=0.0057)...
  20. doi request reprint Abnormal pulmonary function and associated risk factors in children and adolescents with sickle cell anemia
    Manuel Arteta
    Department of Medicine, University of Michigan, Ann Arbor, MI Center for Sickle Cell Disease, Howard University Department of Pediatrics, Children s National Medical Center, Washington, DC Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD Department of Medicine, University of Pittsburgh, Pittsburgh, PA Sickle Cell Center, University of Illinois, Chicago, IL
    J Pediatr Hematol Oncol 36:185-9. 2014
    ..Full pulmonary function testing should be performed in children with hemoglobin SS or Sβ-thalassemia, especially with history of asthma or wheezing and accentuated elevations in hemolytic markers. ..
  21. doi request reprint Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia
    Caterina P Minniti
    Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland
    Am J Hematol 89:1-6. 2014
    ....
  22. pmc Circulating blood endothelial nitric oxide synthase contributes to the regulation of systemic blood pressure and nitrite homeostasis
    Katherine C Wood
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Arterioscler Thromb Vasc Biol 33:1861-71. 2013
    ..A functional red cell eNOS that modulates vascular NO• signaling has been proposed...
  23. pmc Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia
    Deepika S Darbari
    Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    J Pediatr 160:286-90. 2012
    ....
  24. pmc Echocardiographic markers of elevated pulmonary pressure and left ventricular diastolic dysfunction are associated with exercise intolerance in adults and adolescents with homozygous sickle cell anemia in the United States and United Kingdom
    Vandana Sachdev
    Cardiovascular and Pulmonary Medicine Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 124:1452-60. 2011
    ....
  25. pmc Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study
    A Kyle Mack
    Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 142:971-8. 2008
    ..The unique pharmacological properties of nitrite as a hypoxia-potentiated vasodilator and cytoprotective agent in the setting of ischaemia-reperfusion injury make this anion a plausible NO donor for future clinical trials in SCD...
  26. doi request reprint Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels
    Heather M Scoffone
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Bethesda, Maryland Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
    Am J Cardiol 112:1499-504. 2013
    ..Thus, the relatively small changes in HDL-C levels achieved by the dose of niacin-ER used in our study are not associated with improved vascular function in patients with SCD with initially low levels of apoA-I or HDL-C...
  27. pmc Diet-induced weight loss in overweight or obese women and changes in high-density lipoprotein levels and function
    Brittany O Aicher
    Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
    Obesity (Silver Spring) 20:2057-62. 2012
    ....
  28. pmc Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease
    Vandana Sachdev
    Cardiovascular Branch, Echocardiography Laboratory, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 1454, USA
    J Am Coll Cardiol 49:472-9. 2007
    ..The goal of this study was to characterize left ventricular diastolic function in the sickle cell disease (SCD) population and to relate echocardiographic measures of dysfunction with pulmonary hypertension and mortality...
  29. pmc Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review
    Jane A Little
    Vascular Medicine Branch, National Heart Lung and Blood Institute, Clinical Center, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Haematologica 91:1076-83. 2006
    ..Furthermore EPO appears to be safe in SCD, particularly when used in conjunction with HU. We outline our current therapeutic strategy for EPO use in SCD...
  30. pmc Leg ulcers in sickle cell disease: current patterns and practices
    Kara Marie H Delaney
    National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892 1476, USA
    Hemoglobin 37:325-32. 2013
    ..Despite their frequency, there is no clear consensus among providers as to the best treatment. ..
  31. pmc Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease
    Alexander M Gorbach
    Infrared Imaging and Thermometry Unit, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, MD, USA
    Microvasc Res 84:262-9. 2012
    ..Measurement of baseline skin temperature by IR imaging may be a useful new marker of vascular risk in adults with SCD...
  32. pmc Infusion of hemolyzed red blood cells within peripheral blood stem cell grafts in patients with and without sickle cell disease
    Courtney D Fitzhugh
    Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute NHLBI National Institute of Diabetes and Digestive and Kidney Diseases NIDDK, National Institutes of Health NIH, Bethesda, MD 20892, USA
    Blood 119:5671-3. 2012
    ..Our data do not support free hemoglobin as a significant contributor to toxicity associated with PBSC infusions. This study was registered at clinicaltrials.gov (NCT00631787)...
  33. pmc Sickle cell disease and nitric oxide: a paradigm shift?
    A Kyle Mack
    Pediatric Oncology Branch, 10 Center Drive, MSC 1476, NCI, NIH, Bethesda, MD 20892 1476, United States
    Int J Biochem Cell Biol 38:1237-43. 2006
    ..Therapies directed at decreasing the destruction of nitric oxide, increasing the production of nitric oxide, or amplifying the nitric oxide response may prove beneficial...
  34. pmc Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease
    Susan Yuditskaya
    Pulmonary and Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1476, USA
    Blood 113:1122-8. 2009
    ..These results imply a relationship of apolipoproteins to the development of PAH vasculopathy in SCD, potentially involving an unexpected mechanistic parallel to atherosclerosis, another proliferative vasculopathy...
  35. pmc Severe pulmonary hypertension in an adolescent with sickle cell disease
    James G Taylor
    Vascular Medicine Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892 1476, USA
    Am J Hematol 83:71-2. 2008
  36. pmc Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study
    Deepika S Darbari
    Center for Cancer and Blood Disorders, Children s National Medical Center, Washington DC, United States of America Genomic Medicine Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 8:e79923. 2013
    ..The current study sought to determine the relevance of the association between more frequent VOCs and death and its relative impact upon overall mortality compared to other known risk factors in a contemporary adult SCA cohort...
  37. pmc Hemodynamic predictors of mortality in adults with sickle cell disease
    Alem Mehari
    Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Am J Respir Crit Care Med 187:840-7. 2013
    ..Pulmonary hypertension (PH) in adults with sickle cell disease (SCD) is associated with early mortality, but no prior studies have evaluated quantitative relationships of mortality to physiological measures of pre- and postcapillary PH...
  38. pmc Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications
    Jonathan C Goldsmith
    Blood Diseases Branch, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 7950, USA
    Am J Hematol 87:340-6. 2012
    ..The goal of the workshop was to identify potential research questions to address knowledge gaps...
  39. pmc Haptoglobin halts hemoglobin's havoc
    Gregory J Kato
    Sickle Cell Vascular Disease Section, Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, and Critical Care Medicine Department, Clinical Center, National Institutes of Health, Maryland 20892 1476, USA
    J Clin Invest 119:2140-2. 2009
    ..Hp prevented Hb-induced hypertension and the generation of oxidant damage to the kidney. Neutralization of free Hb appears to be part of the downstream antiinflammatory properties of glucocorticoid...
  40. ncbi request reprint Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management
    Zakari Y Aliyu
    Vascular Medicine Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892 1662, USA
    Am J Hematol 83:63-70. 2008
    ..There is clearly a need to include Africa and other parts of the world with high SCD prevalence in future comprehensive studies on the epidemiology and treatment of end organ complications of an aging SCD population world-wide...
  41. pmc Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension
    Roberto F Machado
    Vascular Therapeutics Section, Cardiovascular Branch, National Heart Lung and Blood Institute, Bethesda, MD, USA
    Br J Haematol 130:445-53. 2005
    ....
  42. pmc Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria
    Zakari Y Aliyu
    Department of Medicine and Center for Sickle Cell Disease, Howard University, Washington, District of Columbia 20060, USA
    Am J Hematol 83:485-90. 2008
    ..The inclusion of African sites in sickle cell pulmonary hypertension clinical trials should be encouraged...
  43. pmc Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia
    Chutima Kumkhaek
    Molecular and Clinical Hematology Branch, NIDDK, NIH, Bethesda, MD, USA
    Br J Haematol 141:254-9. 2008
    ..These data suggest that variation within SAR1A regulatory elements might contribute to inter-individual differences in regulation of HbF expression and patient responses to HC in SCD...
  44. pmc Pulmonary hypertension in sickle cell disease: relevance to children
    Gregory J Kato
    Vascular Medicine Branch, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
    Pediatr Hematol Oncol 24:159-70. 2007
    ..Hemolysis-associated PAH with impairments in NO bioavailability is being identified in thalassemia and other hemolytic disorders, and may be a general consequence of long-standing, severe intravascular hemolytic anemia...
  45. pmc Imaging flow cytometry for morphologic and phenotypic characterization of rare circulating endothelial cells
    Leigh Samsel
    Flow Cytometry Core Facility, National Heart Lung and Blood Institute, NIH, Bethesda, Maryland
    Cytometry B Clin Cytom 84:379-89. 2013
    ..Thus, this method will enable a broad range of novel studies to be conducted using CECs as surrogates of the endothelium...
  46. pmc A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease
    Nalini Raghavachari
    Genomics Core Facility, Genetics and Development Biology, NHLBI, The National Institutes of Health, 10 Center Drive, Bldg 10, 8C 103B, Bethesda, MD 20892, USA
    BMC Med Genomics 5:28. 2012
    ..The field of transcriptomics is currently being revolutionized by high throughput DNA sequencing methodologies to map, characterize, and quantify the transcriptome...
  47. pmc High-density lipoprotein cholesterol efflux, nitration of apolipoprotein A-I, and endothelial function in obese women
    Edward Vazquez
    Cardiovascular Pulmonary Branch, Proteomics Core Facility and Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Cardiol 109:527-32. 2012
    ..This finding suggests that the functional measures of HDL might be better markers for cardiovascular risk than the HDL cholesterol levels in this population...
  48. pmc The proteome of sickle cell disease: insights from exploratory proteomic profiling
    Susan Yuditskaya
    Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Expert Rev Proteomics 7:833-48. 2010
    ..Exploratory proteomic profiling is a valuable source of hypothesis generation for the cellular and molecular pathophysiology of sickle cell disease...
  49. pmc Current therapy of sickle cell disease
    Zakari Y Aliyu
    Haematologica 91:7-10. 2006
  50. pmc Hemolysis-associated pulmonary hypertension in thalassemia
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center at Oakland, 747 52nd Street, Oakland, California 94609, USA
    Ann N Y Acad Sci 1054:481-5. 2005
    ..Erythrocyte release of arginase during hemolysis contributes to the development of PHT. Therapies that maximize arginine and nitric oxide bioavailability may benefit patients with thalassemia...
  51. pmc Corticosteroids and increased risk of readmission after acute chest syndrome in children with sickle cell disease
    John J Strouse
    Division of Pediatric Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Pediatr Blood Cancer 50:1006-12. 2008
    ..We performed a retrospective cohort study to evaluate risk factors for readmission and prolonged hospitalization after different treatments for ACS...
  52. pmc Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease
    Claudia R Morris
    Department of Emergency Medicine, Children s Hospital and Research Center at Oakland, CA 94609, USA
    JAMA 294:81-90. 2005
    ..We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes...
  53. doi request reprint Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!
    Mark T Gladwin
    Haematologica 93:1-3. 2008
  54. pmc A network model to predict the risk of death in sickle cell disease
    Paola Sebastiani
    Boston University School of Public Health, MA 02118, USA
    Blood 110:2727-35. 2007
    ..The severity score could serve as an estimate of overall disease severity in genotype-phenotype association studies, and the model provides an additional method to study the complex pathophysiology of sickle cell disease...